biopharma-reporter5 天
Atalanta Therapeutics raises $97 million to advance RNAi therapies for CNS disorders
The oversubscribed Series B will boost the clinical development of two RNAi therapies for epilepsy and Huntington’s disease ...
biopharma-reporter5 天
Inhibikase to pause development of Parkinson’s drug
Inhibikase Therapeutics announced disappointing results from a Phase 2 trial for its Parkinson’s disease drug, risvodetinib, ...
biopharma-reporter7 天
Roche’s Elevidys demonstrates significant benefits for DMD patients in Phase 3
The Swiss pharma giant Roche announced yesterday that the first approved gene therapy for the treatment of Duchenne muscular dystrophy (DMD), Elevidys, demonstrated statistically significant ...
biopharma-reporter7 天
Akero Therapeutics succeeds with MASH liver treatment at phase 2
Akero Therapeutics announced statistically significant results from a Phase 2b trial of its lead therapeutic candidate efruxifermin (EFX) this week, a fibroblast growth factor 21 analog, designed to ...